Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Mucosal Lentiginous Melanoma × nilotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 52 Leukemia 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Gastrointestinal Stromal Tumors 11 Leukemia, Myeloid, Chronic-Phase 10 Neoplasms 4 Blast Crisis 4 Recurrence 3 Bronchiolitis Obliterans Syndrome 3 Synovitis, Pigmented Villonodular 2 Philadelphia Chromosome 2 Melanoma 2 Leukemia, Myeloid, Accelerated Phase 2 Hematologic Diseases 2 Piebaldism 1 Neurofibromatoses 1 Neurofibroma, Plexiform 1 Neurofibroma 1 Neoplastic Processes 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Mucosal Lentiginous Melanoma 1 Mastocytosis, Systemic 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid 1 Hypereosinophilic Syndrome 1 Glioma 1 Giant Cell Tumor of Tendon Sheath 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01395121 2017-06-08

NICAM

Institute of Cancer Research, United Kingdom

Phase 2 Completed

Mucosal Lentiginous Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡